vs
Side-by-side financial comparison of ASGN Inc (ASGN) and Insulet Corporation (PODD). Click either name above to swap in a different company.
ASGN Inc is the larger business by last-quarter revenue ($970.0M vs $783.7M, roughly 1.2× Insulet Corporation). Insulet Corporation runs the higher net margin — 13.0% vs 0.6%, a 12.4% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs -3.0%). Insulet Corporation produced more free cash flow last quarter ($48.2M vs $9.1M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs -3.2%).
ASGN Inc is a leading U.S.-headquartered professional services and workforce solutions provider. It specializes in supplying skilled talent and consulting services across high-growth segments including information technology, creative, digital, life sciences, and engineering, primarily serving enterprise clients across North America.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
ASGN vs PODD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $970.0M | $783.7M |
| Net Profit | $5.5M | $101.6M |
| Gross Margin | 27.5% | 72.6% |
| Operating Margin | 2.9% | 18.7% |
| Net Margin | 0.6% | 13.0% |
| Revenue YoY | -3.0% | 31.2% |
| Net Profit YoY | -73.7% | 0.9% |
| EPS (diluted) | $0.13 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $970.0M | — | ||
| Q4 25 | $980.1M | $783.7M | ||
| Q3 25 | $1.0B | $706.3M | ||
| Q2 25 | $1.0B | $649.1M | ||
| Q1 25 | $968.3M | $569.0M | ||
| Q4 24 | $985.0M | $597.5M | ||
| Q3 24 | $1.0B | $543.9M | ||
| Q2 24 | $1.0B | $488.5M |
| Q1 26 | $5.5M | — | ||
| Q4 25 | $25.2M | $101.6M | ||
| Q3 25 | $38.1M | $87.6M | ||
| Q2 25 | $29.3M | $22.5M | ||
| Q1 25 | $20.9M | $35.4M | ||
| Q4 24 | $42.4M | $100.7M | ||
| Q3 24 | $47.5M | $77.5M | ||
| Q2 24 | $47.2M | $188.6M |
| Q1 26 | 27.5% | — | ||
| Q4 25 | 28.9% | 72.6% | ||
| Q3 25 | 29.4% | 72.2% | ||
| Q2 25 | 28.7% | 69.7% | ||
| Q1 25 | 28.4% | 71.9% | ||
| Q4 24 | 29.0% | 72.1% | ||
| Q3 24 | 29.1% | 69.3% | ||
| Q2 24 | 29.1% | 67.7% |
| Q1 26 | 2.9% | — | ||
| Q4 25 | 5.7% | 18.7% | ||
| Q3 25 | 6.7% | 16.7% | ||
| Q2 25 | 5.8% | 18.7% | ||
| Q1 25 | 4.8% | 15.6% | ||
| Q4 24 | 7.5% | 18.3% | ||
| Q3 24 | 7.7% | 16.2% | ||
| Q2 24 | 7.8% | 11.2% |
| Q1 26 | 0.6% | — | ||
| Q4 25 | 2.6% | 13.0% | ||
| Q3 25 | 3.8% | 12.4% | ||
| Q2 25 | 2.9% | 3.5% | ||
| Q1 25 | 2.2% | 6.2% | ||
| Q4 24 | 4.3% | 16.9% | ||
| Q3 24 | 4.6% | 14.2% | ||
| Q2 24 | 4.6% | 38.6% |
| Q1 26 | $0.13 | — | ||
| Q4 25 | $0.58 | $1.42 | ||
| Q3 25 | $0.87 | $1.24 | ||
| Q2 25 | $0.67 | $0.32 | ||
| Q1 25 | $0.48 | $0.50 | ||
| Q4 24 | $0.94 | $1.38 | ||
| Q3 24 | $1.06 | $1.08 | ||
| Q2 24 | $1.02 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $143.6M | — |
| Total DebtLower is stronger | $1.5B | $930.8M |
| Stockholders' EquityBook value | $1.8B | $1.5B |
| Total Assets | $4.0B | $3.2B |
| Debt / EquityLower = less leverage | 0.82× | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $143.6M | — | ||
| Q4 25 | $161.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $205.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.2B | $930.8M | ||
| Q3 25 | $1.2B | $934.9M | ||
| Q2 25 | $1.2B | $939.0M | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.0B | $1.3B | ||
| Q3 24 | $1.0B | $1.4B | ||
| Q2 24 | $1.0B | $1.4B |
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $1.5B | ||
| Q3 25 | $1.8B | $1.4B | ||
| Q2 25 | $1.8B | $1.5B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $1.8B | $1.2B | ||
| Q3 24 | $1.8B | $1.1B | ||
| Q2 24 | $1.8B | $998.4M |
| Q1 26 | $4.0B | — | ||
| Q4 25 | $3.7B | $3.2B | ||
| Q3 25 | $3.7B | $3.0B | ||
| Q2 25 | $3.7B | $3.5B | ||
| Q1 25 | $3.7B | $3.5B | ||
| Q4 24 | $3.4B | $3.1B | ||
| Q3 24 | $3.4B | $3.0B | ||
| Q2 24 | $3.5B | $2.9B |
| Q1 26 | 0.82× | — | ||
| Q4 25 | 0.65× | 0.61× | ||
| Q3 25 | 0.64× | 0.68× | ||
| Q2 25 | 0.66× | 0.64× | ||
| Q1 25 | 0.72× | 1.21× | ||
| Q4 24 | 0.58× | 1.07× | ||
| Q3 24 | 0.58× | 1.21× | ||
| Q2 24 | 0.57× | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $183.3M |
| Free Cash FlowOCF − Capex | $9.1M | $48.2M |
| FCF MarginFCF / Revenue | 0.9% | 6.2% |
| Capex IntensityCapex / Revenue | 1.0% | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $290.6M | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $102.3M | $183.3M | ||
| Q3 25 | $83.9M | $125.7M | ||
| Q2 25 | $124.9M | $196.5M | ||
| Q1 25 | $16.8M | $63.8M | ||
| Q4 24 | $100.2M | $147.7M | ||
| Q3 24 | $135.8M | $98.5M | ||
| Q2 24 | $90.7M | $96.5M |
| Q1 26 | $9.1M | — | ||
| Q4 25 | $93.7M | $48.2M | ||
| Q3 25 | $72.0M | $100.1M | ||
| Q2 25 | $115.8M | $177.9M | ||
| Q1 25 | $6.6M | $51.5M | ||
| Q4 24 | $88.9M | $94.1M | ||
| Q3 24 | $127.9M | $71.8M | ||
| Q2 24 | $85.4M | $74.0M |
| Q1 26 | 0.9% | — | ||
| Q4 25 | 9.6% | 6.2% | ||
| Q3 25 | 7.1% | 14.2% | ||
| Q2 25 | 11.3% | 27.4% | ||
| Q1 25 | 0.7% | 9.1% | ||
| Q4 24 | 9.0% | 15.7% | ||
| Q3 24 | 12.4% | 13.2% | ||
| Q2 24 | 8.3% | 15.1% |
| Q1 26 | 1.0% | — | ||
| Q4 25 | 0.9% | 17.2% | ||
| Q3 25 | 1.2% | 3.6% | ||
| Q2 25 | 0.9% | 2.9% | ||
| Q1 25 | 1.1% | 2.2% | ||
| Q4 24 | 1.1% | 9.0% | ||
| Q3 24 | 0.8% | 4.9% | ||
| Q2 24 | 0.5% | 4.6% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | 1.80× | ||
| Q3 25 | 2.20× | 1.43× | ||
| Q2 25 | 4.26× | 8.73× | ||
| Q1 25 | 0.80× | 1.80× | ||
| Q4 24 | 2.36× | 1.47× | ||
| Q3 24 | 2.86× | 1.27× | ||
| Q2 24 | 1.92× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASGN
Segment breakdown not available.
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
